0
SELLAS Life Sciences Group, Inc. Banner Image

SELLAS Life Sciences Group, Inc. has reached its limit for free report views

Work for SELLAS Life Sciences Group, Inc.? Upgrade Your Profile and unlock all your annual reports.

SELLAS Life Sciences Group, Inc.

  • Ticker SLS
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
SELLAS Life Sciences Group, Inc. Logo Image
  • 1-10 Employees
  • Based in Zurich, Switzerland
SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to addressMore a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS’ second product candidate, nelipepimut-S, is a HER2-directed cancer immunotherapy with potential for the treatment of patients with early stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer patients, following standard of care.
SELLAS Life Sciences Group, Inc.

Most Recent Annual Report

SELLAS Life Sciences Group, Inc. MOST RECENT 2020 Annual Report and Form 10K

Report Locked. SELLAS Life Sciences Group, Inc. has reached its limit for free report views.

Older/Archived Annual Reports